Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trial.

ESC heart failure - 1 Dec 2024

Garcia-Pavia Pablo, Lakdawala Neal K, Sinagra Gianfranco, Ripoll-Vera Tomas, Afshar Kia, Priori Silvia G, Ware James S, Owens Anjali, Li Huihua, Angeli Franca S, Elliott Perry, MacRae Calum A, Judge Daniel P

Abstract excerpt

AIMS: LMNA-related dilated cardiomyopathy (DCM) is a rare disease with an incompletely defined phenotype. The phase 3 REALM-DCM trial evaluated a potential disease-modifying therapy for LMNA-related DCM but was terminated due to futility without safety concern. This study utilized pooled data from REALM-DCM to descriptively characterize the phenotype and progression of LMNA-related DCM in a contemporary cohort of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cardiomyopathy, Dilated

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Defibrillators, Implantable

Share to Disease Progression

Share to Follow-Up Studies

Share to Lamin Type A

Share to Phenotype

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 39145700
DOI: 10.1002/ehf2.14955
PMCID: PMC11631308

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trial.PMID 39145700Read ↗

[Non-dilated left ventricular cardiomyopathy: beyond morphology, towards diagnostic precision].Semantic proximity Read ↗

LMNA-related cardiomyopathy: From molecular pathology to cardiac gene therapySemantic proximity Read ↗

LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician.Semantic proximity Read ↗

LMNA cardiomyopathy: cell biology and genetics meet clinical medicineSemantic proximity Read ↗

High-Risk Cardiomyopathy Genotypes and Arrhythmic Risk: LMNA, FLNC, RBM20, PLN and Desmosomal Genes in the ESC 2023 Era.Semantic proximity Read ↗

Updated clinical overview on cardiac laminopathies: an electrical and mechanical diseaseSemantic proximity Read ↗

Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers.Semantic proximity Read ↗

A novel LMNA nonsense mutation causes two distinct phenotypes of cardiomyopathy with high risk of sudden cardiac death in a large five-generation family.Semantic proximity Read ↗

Location of LMNA Variants and Clinical Outcomes in CardiomyopathySemantic proximity Read ↗

Frequency, Penetrance, and Variable Expressivity of Dilated Cardiomyopathy–Associated Putative Pathogenic Gene Variants in UK Biobank ParticipantsSemantic proximity Read ↗

Emerging Genotype-Phenotype Associations in Dilated Cardiomyopathy.Semantic proximity Read ↗

Lamin and the heart.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.